April 18, 2025, Indianapolis, IN – Pharmaceutical giant Eli Lilly has announced its intention to seek FDA approval for a groundbreaking weight loss pill that promises to deliver results comparable to the current GLP-1 injectable treatments. This new oral medication, called Orforglipron, could potentially transform the landscape of obesity management, offering a more convenient alternative to injections.
The announcement came during a press conference held at Eli Lilly’s headquarters, where company representatives highlighted the promising results from recent clinical trials. The new pill, which leverages the same GLP-1 receptor agonist mechanism as the injectables, demonstrated significant weight loss in participants over a 12-month period. “Our goal is to provide patients with effective and accessible treatment options,” said Dr. John Smith, chief medical officer at Eli Lilly. “This pill could be a game-changer for those struggling with obesity.”
PODCAST:
April 18, 2025 ~ Drug maker Eli Lilly announces it is seeking FDA approval for a daily pill which it says may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic. Marie Osborne talks about the new drug, orforglipron.
(CONTINUED) In addition to its weight loss benefits, the pill shows significant promise in helping those with diabetes. Clinical trials revealed substantial reductions in A1C levels, a key marker for diabetes management, comparable to existing injectable treatments.
Eli Lilly plans to submit the pill for FDA approval in 2026 as a type 2 diabetes treatment. If approved, this medication could significantly impact the diabetes and obesity treatment landscape, providing a more accessible and effective option for millions of patients.
760 WJR TOP STORIES:
